Studies on the cyclosporin A loaded stearic acid nanoparticles

被引:90
作者
Zhang, QN
Yie, GQ
Li, Y
Yang, QS
Nagai, YT
机构
[1] Hoshi Univ, Dept Pharmaceut, Shinagawa Ku, Tokyo 142, Japan
[2] Beijing Med Univ, Sch Pharmaceut Sci, Dept Pharm, Beijing 100083, Peoples R China
关键词
drug carrier; stearic acid; nanoparticles; cyclosporin A; relative bioavailability;
D O I
10.1016/S0378-5173(00)00361-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Stearic acid nanoparticles were prepared in this study by melt-homogenization to investigate the possibility of them as a new kind of drug carrier system. Some physicochemical properties of stearic acid nanoparticles were studied and morphology examined by transmission electron microscope. Cyclosporin A as a model drug was then encapsulated into stearic acid nanoparticles. Following the establishment of high performance liquid chromatography assay for cyclosporin A analysis in stearic acid nanoparticles or blood samples, the encapsulation ratio of cyclosporin A to stearic acid nanoparticles was estimated and pharmacokinetics as well as bioavailability of cyclosporin A stearic acid nanoparticles after oral administration to Wistar rats were studied, using the Sandimmun Neoral(R) (an available microemulsion system of cyclosporin A) as a reference. The mean diameter of cyclosporin A stearic acid nanoparticles was 316.1 nm, while the encapsulation ratio of cyclosporin A to stearic acid nanoparticles reached to 88.36%. It was demonstrated by 1R spectra and differential scanning calorimetry that there was no chemical reaction occurred between the cyclosporin A and stearic acid. The relative bioavailability of cyclosporin A stearic acid nanoparticles over reference was nearly 80%, and the time to reach maximum concentration (T-max) of cyclosporin A after oral administration of cyclosporin A stearic acid nanoparticles was delayed significantly than the reference, suggesting an obvious sustained release effect. The stearic acid nanoparticles might be a very potential drug carrier. (C) 2000 Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:153 / 159
页数:7
相关论文
共 8 条
[1]   Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats [J].
Bargoni, A ;
Cavalli, R ;
Caputo, O ;
Fundarò, A ;
Gasco, MR ;
Zara, GP .
PHARMACEUTICAL RESEARCH, 1998, 15 (05) :745-750
[2]   Spray-drying of solid lipid nanoparticles (SLN™) [J].
Freitas, C ;
Muller, RH .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1998, 46 (02) :145-151
[3]   Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase [J].
Freitas, C ;
Müller, RH .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1999, 47 (02) :125-132
[4]   Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization [J].
Heiati, H ;
Tawashi, R ;
Phillips, NC .
JOURNAL OF MICROENCAPSULATION, 1998, 15 (02) :173-184
[5]   NMR relaxometric investigations of solid lipid nanoparticles (SLN) containing gadolinium(III) complexes [J].
Morel, S ;
Terreno, E ;
Ugazio, E ;
Aime, S ;
Gasco, MR .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1998, 45 (02) :157-163
[6]   Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN) [J].
Schwarz, C ;
Mehnert, W .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 157 (02) :171-179
[7]   Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles [J].
Siekmann, Britta ;
Westesen, Kirsten .
Colloids and Surfaces B: Biointerfaces, 1994, 3 (03) :159-175
[8]  
梁玉, 1992, 中华医学检验杂志, V15, P206